Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections.
Ackermann M, Kempf H, Hetzel M, Hesse C, Hashtchin AR, Brinkert K, Schott JW, Haake K, Kühnel MP, Glage S, Figueiredo C, Jonigk D, Sewald K, Schambach A, Wronski S, Moritz T, Martin U, Zweigerdt R, Munder A, Lachmann N.
Ackermann M, et al.
Nat Commun. 2018 Nov 30;9(1):5088. doi: 10.1038/s41467-018-07570-7.
Nat Commun. 2018.
PMID: 30504915
Free PMC article.